Skip to Content
Merck
CN
  • [Intraosseous blocks in the treatment of symmetrical distal diabetic polyneuropathy].

[Intraosseous blocks in the treatment of symmetrical distal diabetic polyneuropathy].

Terapevticheskii arkhiv (2013-07-03)
E L Sokov, L E Kornilova, O P Artiukov
ABSTRACT

To evaluate the efficiency of intraosseous blocks (IOB) in the combination treatment of patients with painful diabetic symmetrical distal polyneuropathy (DSDP) of the lower limbs. Seventy-eight patients with painful DSDP were examined. Its diagnosis was verified by neurological examination, assessments of the data of the neuropathic pain diagnostic (DN4) questionnaire and electroneuromyography (ENMG). The pain syndrome was evaluated with a combined visual analogue scale (VAS). The degree of DSDP was estimated using the total symptoms score (TSS) and the neuropathy impairment scale-lower limbs (NIS-LL) scale. The Spielberger questionnaire was used to evaluate reactive and trait anxiety and the Beck inventory was employed to estimate the level of depression. A study group comprised 40 patients receiving IOB as part of the standard treatment. A control group consisted of 38 patients taking oral amitriptyline as a component of the standard treatment. Therapeutic effectiveness was evaluated, by changing the neurological status, trends in VAS, TSS, and NIS-LL scores, and data of psychological questionnaires and ENMG before and after the course of therapy and 1, 3, and 6 months after treatment. IOB was found to be highly effective in pain syndrome, affective disorders, and other manifestations of DSDP; moreover, the therapeutic effect persisted within 6 months after treatment.

MATERIALS
Product Number
Brand
Product Description

Supelco
Lidocaine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Amitriptyline hydrochloride, ≥98% (TLC), powder
Sigma-Aldrich
Lidocaine hydrochloride monohydrate, solid
Supelco
Lidocaine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Lidocaine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Lidocaine, European Pharmacopoeia (EP) Reference Standard
Lidocaine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Supelco
Amitriptyline hydrochloride solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®